Antifection

11-Deacetoxywortmannin is an antibiotic that targets fungal pathogens, derived from Aspergillus janus and Penicillium funiculosum. It exhibits potent antifungal and anti-inflammatory properties, making it valuable in research focused on managing fungal infections and inflammatory conditions. Additionally, its anti-edema effects contribute to its potential therapeutic applications in various biomedical studies.

Monamycin H1 is an ester peptide antibiotic that primarily targets Gram-positive bacteria. It exhibits potent antimicrobial activity, making it a valuable resource for research applications focused on bacterial infections and resistance mechanisms. Monamycin H1 can be utilized in studies investigating antibiotic efficacy and developmental pharmacology.

1-Deamino-1-hydroxygentamicin C1a is an aminoglycoside antibiotic that exhibits potent activity against both Gram-positive and Gram-negative bacteria. This compound functions by inhibiting bacterial protein synthesis, making it a valuable tool for studying bacterial resistance mechanisms and antibiotic efficacy. Its antimicrobial properties make it suitable for research applications focusing on infectious diseases and antibiotic development.

Viomycin is a potent antibiotic specifically targeting Mycobacteria. It acts by rapidly inhibiting polypeptide chain elongation during protein synthesis in bacterial ribosomes, particularly within purified Escherichia coli polysomes. Viomycin is primarily utilized in research focused on mycobacterial infections and the mechanisms of antibiotic resistance.

Mureidomycin D is an antibiotic that exhibits potent activity against Pseudomonas aeruginosa. This compound targets bacterial cell wall synthesis, disrupting the growth of pathogenic strains. Mureidomycin D is utilized in research applications focused on combating antibiotic-resistant infections and studying the mechanisms of bacterial resistance.

Endophenazine D is a phenazine antibiotic that exerts its antimicrobial effects through interference with DNA synthesis and cellular respiration. This compound demonstrates significant activity against a range of bacterial strains, making it an important tool in microbiological research. Its applications include studying antibiotic resistance mechanisms and evaluating potential therapeutic strategies in infectious disease models.

Cefluprenam is a β-lactam antibiotic that targets bacterial cell wall synthesis, exhibiting broad-spectrum antibacterial activity. This compound is effective against a range of Gram-positive and Gram-negative organisms, making it suitable for research in antibiotic resistance and bacterial infection studies. Cefluprenam serves as a valuable tool in microbiological applications aimed at understanding and combating bacterial pathogens.

Clindamycin palmitate is an antibacterial agent that undergoes rapid hydrolysis in vivo, converting to the active form, clindamycin, which effectively targets bacterial infections. This prodrug is primarily used in research to study antibiotic efficacy and mechanisms of action. Its application extends to exploring resistance patterns and enhancing the understanding of bacterial pathogenesis.

Lipohexin is a peptide antibiotic that targets Gram-positive bacteria. It exhibits significant antibacterial activity, as evidenced by its competitive inhibition of human placental proline endopeptidase, with an IC50 of 3.5 μM. Additionally, Lipohexin inhibits proline endopeptidase from Flavobacterium meningoseptica, with an IC50 of 25 μM, making it a valuable reagent for research in antibiotic development and enzyme inhibition studies.

Arylomycin B7 is a lipohexapeptide antibiotic that targets Gram-positive bacteria. It exhibits potent antibacterial activity by inhibiting bacterial protein synthesis. This compound is valuable for research into antibiotic mechanisms and the development of new therapeutic agents against resistant pathogens.

Dynemicin O is an antibiotic that exerts potent activity against Gram-positive bacteria. Its mechanism involves disruption of bacterial DNA synthesis, making it a valuable tool for studying bacterial resistance and efficacy in antibiotic development. Researchers can utilize Dynemicin O in microbiological studies to better understand the therapeutic potential and limitations of antimicrobial agents.

Napsamycin B is an antibiotic known for its selective antibacterial activity against Pseudomonas aeruginosa and various other Pseudomonas species. While it demonstrates limited effectiveness against other Gram-positive and Gram-negative bacteria, Napsamycin B's specificity makes it a valuable reagent for studying Pseudomonas infections and exploring antibiotic mechanisms in related research applications.

3-O-Demethyl-2'-N-glylfortimicin B is an aminoglycoside antibiotic that primarily targets bacterial ribosomes, inhibiting protein synthesis. This compound exhibits broad-spectrum antibacterial activity, making it valuable in research applications aimed at studying bacterial resistance mechanisms and the pharmacodynamics of aminoglycoside antibiotics. Its unique structural modifications further enhance its stability and efficacy against various pathogenic strains.

Argimicin B is an antibiotic derived from Sphingomonas sp., exhibiting potent algicidal activity against various toxic cyanobacteria. With a minimum inhibitory concentration (MIC) in the low micromolar range, it serves as an effective agent for studying cyanobacterial blooms and their ecological impacts. Its unique mode of action makes Argimicin B a valuable tool in environmental microbiology and phytoplankton research applications.

Dynemicin P is a potent antibiotic primarily targeting bacterial cell wall synthesis. It exhibits significant antibacterial activity, making it valuable for research applications focused on studying gram-positive bacterial infections. Its unique mechanism of action provides insights into antibiotic resistance and the development of new therapeutic strategies.

Pacidamycin D is an antibiotic that specifically targets Pseudomonas aeruginosa. It exhibits antimicrobial activity with a minimum inhibitory concentration (MIC) ranging from 4 to 16 μg/mL against this strain. However, it shows no efficacy against other Gram-negative and Gram-positive bacteria, including drug-resistant variants of Pseudomonas aeruginosa. This compound is useful for research applications focused on bacterial resistance mechanisms and the development of targeted antibiotic therapies.

1-Deamino-1-hydroxygentamicin C2 is an aminoglycoside antibiotic that targets bacterial ribosomes to inhibit protein synthesis. This compound exhibits antibacterial activity against both Gram-positive and Gram-negative bacteria, making it valuable in microbiological research. It is utilized in studies investigating antibiotic resistance and evaluating therapeutic efficacy in bacterial infections.

Antibiotic Adjuvant 3 is a potent colistin-potentiating agent that enhances the efficacy of antibiotics against resistant strains. This compound demonstrates a minimum re-sensitizing concentration of 0.25 μg/mL against Escherichia coli AR-0493, while maintaining low toxicity in mammalian systems. It is particularly valuable in research applications focused on combating antibiotic resistance and improving therapeutic outcomes.

Cefmenoxime sodium is a semisynthetic cephalosporin antibiotic that targets bacterial cell wall synthesis. It exhibits antibacterial activity against a broad spectrum of both gram-positive and gram-negative bacteria. This compound is primarily utilized in microbiological studies and therapeutic applications to combat bacterial infections.

Leucomycin U is a macrolide antibiotic targeting bacterial protein synthesis. This compound exhibits potent activity against Gram-positive bacteria and also shows efficacy against spirochetes, Rickettsia, and Chlamydia. It is suitable for use in microbial research and the study of bacterial resistance mechanisms.

Mannosyl glucosaminide is an aminoglycoside antibiotic that targets bacterial ribosomes, disrupting protein synthesis. It exhibits antibacterial activity against various strains, including mycobacteria and yeast, making it valuable for research in antimicrobial treatments. This compound can be applied in studies investigating the mechanisms of antibiotic resistance and the development of new therapeutic strategies.

Dioxolamycin is an antitumor antibiotic that selectively targets cancer cell activity, particularly in L-1210 cells. It demonstrates significant cytotoxic effects, making it a valuable tool in cancer research and the development of novel therapeutic strategies. Its mechanism of action involves interfering with cellular processes essential for tumor growth and survival, positioning it as a critical compound in the study of antitumor agents.

Katanosin A is a peptide antibiotic that targets Gram-positive bacteria. It exhibits potent antimicrobial activity, making it a valuable tool for research in the study of antibiotic resistance mechanisms and the development of new antimicrobial therapies. Katanosin A is particularly useful in exploring the efficacy of peptide-based antibiotics in clinical applications.

Epithienamycin D is a carbapenem antibiotic that exhibits broad-spectrum antibacterial activity. It is effective against both Gram-positive and Gram-negative bacteria, making it a valuable tool in microbiological research. This compound can be utilized in studies focused on antibiotic resistance and the development of new antimicrobial therapies.

Macquarimicin A is a potent antibiotic known for its ability to inhibit bacterial growth. It demonstrates significant antimicrobial activity against a range of gram-positive and some gram-negative bacteria. This compound is primarily utilized in microbiological research to study antibiotic resistance mechanisms and the effects of antibiotic treatment. Its unique structure and mode of action make Macquarimicin A an important tool for exploring and developing new therapeutic strategies in infectious disease research.

Pristinamycin IIC is an ester peptide antibiotic targeting Gram-positive bacteria. It exhibits potent antibacterial activity against a range of pathogenic strains, making it valuable in studies related to antibiotic resistance and bacterial infections. Research applications include in vitro susceptibility testing and the evaluation of antibiotic efficacy in various clinical scenarios.

Saquayamycin B is an angucycline antibiotic known for its potent antitumor activity. It exhibits significant inhibition against human lung (H-460) and breast cancer (MCF-7) cell lines, demonstrating GI50 values of 12.2 µM and 15.2 µM, respectively. This compound is a valuable tool for research in cancer therapeutics and antibiotic development.

Phleomycin G is a heteropeptide antibiotic that primarily targets bacterial ribosomes. It exhibits potent activity against Gram-positive and some Gram-negative bacteria, as well as mycobacteria. Research indicates that Phleomycin G can prolong the survival of mice with Ehrman's ascites carcinoma and has demonstrated inhibitory effects on various carcinoma types in murine models. This compound is valuable for studies involving bacterial infections and cancer therapeutics.

Pluracidomycin A1 is a carbapenem antibiotic that targets bacterial cell wall synthesis. It exhibits potent activity against both Gram-positive and Gram-negative bacteria while effectively inhibiting β-lactamase enzymes. This makes it a valuable reagent for research focused on antibiotic resistance and the mechanisms of bacterial pathogenicity.

YM 133 is a semisynthetic macrolide antibiotic that exerts potent bactericidal activity. It demonstrates effectiveness against Erythromycin, Josamycin, and Rokitamycin-resistant strains of staphylococci, streptococci, Bacteroides spp., and Clostridium spp., showcasing strong activity against macrolide-resistant bacteria and anaerobic pathogens. This compound is valuable for antibacterial research focusing on resistant infections and macrolide antibiotic efficacy.

Arylomycin B1 is a lipohexapeptide antibiotic targeting Gram-positive bacteria through inhibition of bacterial signal peptidase. It exhibits potent antibacterial activity and serves as a valuable research tool for studying bacterial resistance mechanisms and the development of novel antibiotic therapies. This compound is essential for investigations in microbiology and antibiotic efficacy.

Nafithromycin is an orally available antibiotic that primarily targets bacterial pathogens, effectively inhibiting strains responsible for community-acquired pneumonia, including Streptococcus pneumoniae, Haemophilus influenzae, Moraxella catarrhalis, and methicillin-susceptible Staphylococcus aureus. This compound exhibits a minimum inhibitory concentration (MIC90) of 0.12 mg/liter against macrolide-resistant and telithromycin-insensitive strains of Streptococcus pneumoniae. Nafithromycin is useful in research applications focused on antibiotic resistance and the treatment of respiratory infections.

Hydroxymycotrienin B is an Ansa antibiotic with potent antitumor activity. It effectively inhibits the proliferation of human neck tumor cell lines, demonstrating a stronger inhibitory effect on HPV gene positive cells, such as HeLa, CaSKi, and SiHa, compared to HPV gene negative cells. This compound is of significant interest in cancer research and the development of targeted therapies against HPV-associated malignancies.

Kocurin is a thiazolyl cyclic-peptide antibiotic that primarily targets bacterial protein biosynthesis during the translation phase. It exhibits strong antibacterial activity against Gram-positive bacteria, making it a valuable reagent for research into antimicrobial resistance and the mechanisms of bacterial translation. Kocurin shows no activity against fungi or Gram-negative bacteria, highlighting its selective antibacterial profile.

Griseusin A is a quinone-based antibiotic that primarily targets Gram-positive bacteria. This compound exhibits significant antibacterial activity, making it a valuable tool in the study of bacterial infections and resistance mechanisms. Griseusin A's unique mechanism may provide insights into novel therapeutic approaches for treating Gram-positive bacterial infections.

Rifamexil is an antibiotic derivative of Rifamycin, specifically designed to inhibit bacterial RNA polymerase. It demonstrates effective activity against Mycobacterium avium complex and various other mycobacterial strains. This reagent is valuable for research applications focused on antimicrobial resistance and the development of treatments for mycobacterial infections.

Y-05460M-A is a substituted isocoumarin antibiotic that demonstrates inhibitory activity against both Gram-positive and Gram-negative bacterial strains. Additionally, Y-05460M-A exhibits cytotoxic effects against P388 lymphatic leukemia cells and has been shown to possess antiulcer activity. This compound is a one-carbon lower homologue of PM-04128 and can be synthesized from N-Boc-L-valine, making it a valuable reagent for antimicrobial and anticancer research.

Napyradiomycin C2 is an antibiotic that primarily targets Gram-positive bacteria and mycobacteria. It exhibits significant antibacterial activity, making it a valuable compound for research focused on bacterial infections and resistance mechanisms. Its unique structure and mode of action can facilitate studies in drug development and microbiology.

Rac N-Demethyl promethazine hydrochloride is a metabolite of Phenothiazine, targeting various biological pathways. This compound exhibits antibiotic properties, demonstrating insecticidal, fungicidal, antibacterial, and anthelmintic activities. It is utilized in research applications focused on understanding mechanisms of action in microbial resistance and therapeutic efficacy.

44-Homooligomycin B is an antitumor antibiotic that primarily targets fungal infections. It exhibits potent activity against fungal strains, including Aspergillus, Penicillium, and Fusarium, while lacking effectiveness against yeast and bacteria. Additionally, 44-Homooligomycin B demonstrates moderate antitumor activity in vivo against Colon 26 cancer models, making it a valuable compound for research in oncology and mycology.

RU44790 is a monocyclic beta-lactam antibiotic that demonstrates potent efficacy against gram-negative bacteria and exhibits remarkable resistance to hydrolysis by various beta-lactamases. This compound serves as a valuable tool in antibacterial research, facilitating investigations into bacterial resistance mechanisms and the development of novel therapeutic strategies.

Coumamidine γ2 is an alkaline sugar antibiotic known for its broad-spectrum antibacterial activity, particularly against Pseudomonas aeruginosa. This compound demonstrates efficacy in inhibiting bacterial growth and is valuable for research applications involving antibiotic resistance and infection models. Its unique mechanism offers insights into microbial interactions and potential therapeutic approaches in clinical settings.

Valanimycin is an antibiotic that targets Escherichia coli by interacting with DNA, effectively inhibiting bacterial growth. In addition to its antibacterial properties, Valanimycin demonstrates cytotoxic effects against mouse leukemia cell lines, including L1210, P388/S, and P388/ADR, with IC50 values of 0.79, 2.65, and 1.44 μg/mL, respectively. It also exhibits significant antitumor efficacy in models of ehrlich ascites tumors and L1210 cells in mice, making it a valuable compound for cancer research and antibiotic studies.

Napyradiomycin B1 is an antibiotic that exhibits potent activity against Gram-positive bacteria and mycobacteria. It demonstrates minimal effectiveness against Gram-negative bacteria and fungi. The compound has an IC50 of 2.2 μg/mL in leukemia L-1210 cell lines, highlighting its potential for research in cancer and infectious disease studies.

Nikkomycin Lx is an antibiotic derived from Streptomyces tendae TU901, targeting the inhibition of fungal cell wall synthesis. It exhibits significant anti-Candida albicans activity, making it valuable for studies focused on fungal infections and resistance mechanisms. This reagent is suitable for research applications involving antifungal efficacy and related therapeutic investigations.

Maridomycin IV is a macrolide antibiotic that targets Gram-positive bacteria and mycoplasma. Demonstrating potent antibacterial activity, it effectively protects mice from Gram-positive bacterial infections. This compound is useful in research applications focused on evaluating antibiotic efficacy and understanding bacterial resistance mechanisms.

Cytorhodin X is a cytotoxic antibiotic that targets bacterial and cancer cell proliferation. It effectively inhibits the growth of L1210 murine leukemia cells, demonstrating an ED50 value of 0.36 μM. This compound is valuable for research applications involving cancer treatment and antibiotic efficacy studies.

Micacocidin C is an antibiotic derived from Pseudomonas sp. No. 57, primarily targeting Mycoplasma species. It demonstrates potent antibacterial activity, making it valuable for research applications focused on combating mycoplasmal infections and understanding antibiotic resistance mechanisms.

Cryptosporiopsin is a potent antibacterial agent derived from Cryptosporiopsis sp. and Sporormia affinis. This compound exhibits significant antibacterial activity against a variety of fungi, including basidiomycetes, algal fungi, ascomycetes, and hemiplegia fungi responsible for wood rot. Additionally, Cryptosporiopsin has been shown to inhibit the spore germination of Phytophthora species affecting potatoes, and demonstrates activity against both gram-positive and gram-negative bacteria, making it valuable for antibacterial research applications.

Baumycin A1 is an antitumor antibiotic that primarily exerts its effects through the inhibition of DNA synthesis. It demonstrates significant cytotoxic activity against various cancer cell lines, making it a valuable tool for cancer research. Researchers can utilize Baumycin A1 to explore mechanisms of tumorigenesis and to develop novel therapeutic strategies in oncology.